Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Sold by Woodline Partners LP

Woodline Partners LP trimmed its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 81.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 229,376 shares of the biopharmaceutical company's stock after selling 982,548 shares during the period. Woodline Partners LP owned approximately 0.09% of Lexicon Pharmaceuticals worth $169,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Renaissance Technologies LLC purchased a new position in shares of Lexicon Pharmaceuticals during the fourth quarter worth approximately $38,000. Virtu Financial LLC purchased a new position in shares of Lexicon Pharmaceuticals during the fourth quarter worth approximately $66,000. Schonfeld Strategic Advisors LLC grew its position in shares of Lexicon Pharmaceuticals by 301.5% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 7,558,621 shares of the biopharmaceutical company's stock worth $5,582,000 after acquiring an additional 5,676,021 shares during the last quarter. Boothbay Fund Management LLC purchased a new position in shares of Lexicon Pharmaceuticals during the fourth quarter worth approximately $355,000. Finally, Swiss National Bank grew its position in shares of Lexicon Pharmaceuticals by 34.4% during the fourth quarter. Swiss National Bank now owns 426,600 shares of the biopharmaceutical company's stock worth $315,000 after acquiring an additional 109,100 shares during the last quarter. 74.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Leerink Partnrs lowered shares of Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Wall Street Zen started coverage on shares of Lexicon Pharmaceuticals in a research report on Monday, April 21st. They set a "sell" rating on the stock. Piper Sandler lowered their price objective on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th. Needham & Company LLC reiterated a "hold" rating on shares of Lexicon Pharmaceuticals in a research report on Monday, March 3rd. Finally, HC Wainwright reiterated a "buy" rating and issued a $4.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Friday, March 28th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Lexicon Pharmaceuticals currently has an average rating of "Hold" and a consensus price target of $3.67.

Lexicon Pharmaceuticals Stock Performance

NASDAQ:LXRX traded down $0.02 during midday trading on Friday, reaching $0.64. The stock had a trading volume of 3,021,476 shares, compared to its average volume of 6,618,833. Lexicon Pharmaceuticals, Inc. has a 12-month low of $0.28 and a 12-month high of $2.45. The company has a quick ratio of 7.43, a current ratio of 7.45 and a debt-to-equity ratio of 0.56. The firm has a fifty day simple moving average of $0.58 and a two-hundred day simple moving average of $0.66. The stock has a market cap of $232.19 million, a P/E ratio of -0.86 and a beta of 1.07.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.03. The company had revenue of $1.26 million for the quarter, compared to analyst estimates of $1.26 million. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. On average, equities analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current year.

Lexicon Pharmaceuticals Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.